STOCK TITAN

Avinger to Announce Fourth Quarter Full Year 2020 Results on March 11, 2021

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Avinger, Inc. (NASDAQ:AVGR) will release its financial results for Q4 and full year 2020 after market close on March 11, 2021. The company offers the first intravascular image-guided catheter-based system for diagnosing and treating Peripheral Artery Disease (PAD), which affects over 12 million people in the U.S. A conference call will follow at 1:30 PM PT/4:30 PM ET, with details available on the company’s website. A replay will be accessible post-call.

Positive
  • Avinger is the first company to offer an intravascular image-guided, catheter-based system for PAD treatment, giving it a competitive edge in a growing market.
  • The company anticipates a substantial audience for its Q4 and full year 2020 earnings call, indicating investor interest.
Negative
  • The absence of specific financial metrics in the PR may raise concerns regarding the company’s performance.

REDWOOD CITY, CA / ACCESSWIRE / March 2, 2021 / Avinger, Inc. (NASDAQ:AVGR), commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that it will release its financial results for the fourth quarter and full year 2020 after the close of trading on Thursday, March 11, 2021. The Company will host a conference call beginning at 1:30 pm PT/4:30 pm ET.

To join the call by telephone, please dial +1-201-689-8031. A live webcast of the conference call will be available online from the investor relations page of the Company's corporate website at http://www.avinger.com.

A replay of the webcast will be made available on Avinger's website, www.avinger.com, shortly after completion of the call.

About Avinger, Inc.
Avinger is a commercial-stage medical device company that designs and develops the first and only image-guided, catheter-based system for the diagnosis and treatment of patients with Peripheral Artery Disease (PAD). PAD is estimated to affect over 12 million people in the U.S. and over 200 million worldwide. Avinger is dedicated to radically changing the way vascular disease is treated through its Lumivascular platform, which currently consists of the Lightbox imaging console, the Ocelot and Tigereye™ family of chronic total occlusion (CTO) crossing catheters, and the Pantheris® family of atherectomy devices. Avinger is based in Redwood City, California. For more information, please visit www.avinger.com.

Follow Avinger on Twitter and Facebook.

Investor Contact:
Mark Weinswig
Chief Financial Officer
Avinger, Inc.
(650) 241-7916
ir@avinger.com

Matt Kreps
Darrow Associates Investor Relations
(214) 597-8200
mkreps@darrowir.com

SOURCE: Avinger, Inc.



View source version on accesswire.com:
https://www.accesswire.com/632900/Avinger-to-Announce-Fourth-Quarter-Full-Year-2020-Results-on-March-11-2021

FAQ

When will Avinger announce Q4 and full year 2020 financial results?

Avinger will announce its financial results on March 11, 2021.

What is Avinger's stock symbol?

Avinger trades under the stock symbol AVGR.

What is the focus of Avinger, Inc.?

Avinger specializes in devices for the diagnosis and treatment of Peripheral Artery Disease.

How can I join Avinger's earnings call?

You can join the call by dialing +1-201-689-8031 or via the company's investor relations page online.

Where can I find the replay of Avinger's earnings call?

The replay will be available on Avinger's website shortly after the call concludes.

Avinger, Inc.

NASDAQ:AVGR

AVGR Rankings

AVGR Latest News

AVGR Stock Data

1.76M
2.30M
18.3%
3.82%
5.61%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States of America
REDWOOD CITY